Overview

The highly anticipated and respected 12th annual Clinical Trials in CNS Conference returns to London with a two day content packed agenda featuring new approaches taken in this field towards a number of neurodegenerative disorders, from clinical trial modelling and simulation to the role of biomarkers, the agenda presents a detailed look into many aspects of drug discovery and delivery of CNS therapeutics. This innovative conference will give delegates an opportunity to gain insights through case studies and interactive discussion into the best practices in clinical trials.


>>>>>Event highlights include:
• Learn the importance of understanding the pathophysiology and biology of disease processes with use of biomarkers and imaging techniques
• Discover ways to design late stage clinical trials
• Overcome challenges of delivery within the CNS
• Determine the legal and ethical issues behind sham surgery

KEYNOTE SPEAKERS INCLUDE:
• Larry Alphs, Therapeutic Area Leader, Johnson & Johnson
• Lars Bauer, Senior Medical Director TA CNS, UCB Pharma
• Tom Isaacs, Co-founder, Cure Parkinson’s Trust
• Kyriacos Mitrophanous, Head of Research, Oxford Biomedica
• Mathieu Albasser, Post Doctoral Researcher, Eli Lilly
• Johannes Streffer, Senior Director, Experimental Medicine Europe, Janssen Research & Development
• Warren Hirst, Associate Research Fellow Neurodegeneration Research, Pfizer
• Eric Karran, Director of Research, Alzheimers Research UK

PLUS AN INTERACTIVE POST-CONFERENCE WORKSHOP
20TH NOVEMBER 2013 | MARRIOTT REGENTS PARK HOTEL | LONDON, UK

Defining Clinical Relevance
Workshop Leaders: Susan Mcgoldrick, Managing Director, QCTR
Audrey Jamieson, Business Development Manager, QCTR
08.30 - 12.30


**Book by 31st September 2013 and save £100**


Academic & Group discounts available


Venue: Marriott Hotel Regents Park
Location: London
Country: United Kingdom

Organiser Contact Details:
Jonathan Collins
T: +44 (0)20 7827 6734
jcollins@smi-online.co.uk